Drug Approval | October 18, 2023
Glenmark's current portfolio consists of 188 products authorized for distribution in the US
Multi-million dollar investment augments in-vitro biology capabilities in primary and secondary screening
Lupin enters into BTA with Lupin Manufacturing Solutions
Prateek has more than 23 years of rich experience in Human Resource
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
The USFDA inspectors issued the observations after a product pre-approval inspection of the biologics facility in Bachupally
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Astria will assume full cost and responsibility for the global development and commercialization of the licensed therapeutic program for all indications
Subscribe To Our Newsletter & Stay Updated
